# Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

> **NCT04314531** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 296 (actual)

## Conditions studied

- Active Psoriatic Arthritis

## Interventions

- **DRUG:** TILD
- **DRUG:** matching placebo injections

## Key facts

- **NCT ID:** NCT04314531
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2025-06-04
- **Final completion:** 2026-04
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04314531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04314531, "Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04314531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*